Company intelligence / Profile preview

GW Pharmaceuticals

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

GW Pharmaceuticals successfully commercialized Sativex for spasticity due to multiple sclerosis (approved in >25 countries) and Epidiolex for seizures in Lennox-Gastaut, Dravet syndrome, and tuberous sclerosis complex (FDA and EMA approved). Other programs, such as GWP42006 (cannabidivarin), had mixed clinical results in epilepsy and autism spectrum disorders. The pipeline has ongoing late-stage programs in additional seizure and CNS indications[1][4][7][10].

Therapeutic areas: UrologyPsychiatryNeurologyRare Diseases
Modalities: Small moleculeBiologicCannabinoid-based drug
Industry: Biotech

Partnerships

Bayer (distribution of Sativex in the UK)[1]Strategic collaborations with other pharmaceutical companies for commercialization

Beyond the preview

Go deeper on GW Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW Pharmaceuticals.

Explore the full profile